Improving Lives Through Science

Login | Register

News

News › Esco VacciXcell is Launching the New and Improved TideCell® in the US

Esco VacciXcell is Launching the New and Improved TideCell® in the US


Share

Esco VacciXcell is proud to launch the new TideCell® with enhanced features and now controlled by Siemens HMI/PLC in USA soil.

TideCell® runs on a patented Tide Motion principle for adherent cell bioprocessing coupled with a proprietary closed cell harvesting system that has a recovery rate of 90%. It is the world’s largest single-use linearly-scalable bioreactor for adherent cell scale up to 5,000 L packed-bed volume (bioequivalency of 50,000 L in suspension. TideCell® with closed cell harvesting system is ideal for biomass expansion of adherent cells. It can be used as a seed train for the final culture of cells in suspension or microcarriers.

Enhanced TideCell® now comes in a standard hypoxic condition (suppressed oxygen) which is optimal for the growth of bone marrow-derived mesenchymal stem cells (MSCs) and exosomes. Additionally, the compressed air path comes with a double HEPA and VOC (volatile organic chemicals) filters removing particulates to maintain an ISO Class 5 environment during cell culture. TideCell® also comes with a germicidal UV-C decontamination suitable for BSL 3/4 applications.

Built-in weighing platform and in-house mixer will now replace previous third-party platform for easier setup.

Another significant change in TideCell® is the PLC-based monitoring and control system. Dual redundant systems for critical components such as PLC and pumps are catered for at additional costing. As a default, Esco TideCell® runs on Wonderware SCADA. The new and improved PLC-based monitoring and control system can be connected and configured to SCADA systems that have DeltaV and Pcs7 controls.

The Tide Motion technology is excellent for clients transiting from roller bottles, microcarriers, 2D cell factories, or hyper stacks into a closed culture bioreactor. Same bioprocessing parameters can be utilized and transferred to Tide Motion with minimal setting change. This provides an ultra-scale down process and reduces costs by saving on media, labor, space, utilities, and most importantly, eliminates cross-contamination.

TideCell® has a unique 100% media exchange system and zero shear stress conditions making it ideal for difficult-to-culture viruses for human and animal vaccines, virus-like particles (VLPs), and viral vectors (e.g., adeno-associated virus (AAV) and lentivirus (LV)). A 100% media exchange is also ideal for continuous processing of secreted viruses which allows continuous harvesting of the viruses as the new media is perfused in.

A separate matrix vessel and mixing vessel is used when tide motion technology is applied to bioprocessing. Separating the matrix vessel and mixing vessel permits temperatures to vary for cell and viral culture. Cells can be cultured to confluence at 37°C in 1 mixing vessel, after which 100% of a fresh medium at a lower temperature in a separate mixing vessel can be used for viral culture after virus seeding. This dual temperature control process can potentially produce higher virus titers for specific viral strains or aquaculture vaccines than what can be achieved in typical perfusion systems utilizing microcarriers or other packed bed bioreactors which are only able to culture at 1 set temperature.

TideCell® is the core of Esco Aster, a contract development manufacturing organization (CDMO) that uses single-use adherent bioreactors in bioprocessing needs. This cGMP facility is currently in conceptual design and will be completed by December 2018.

Factory acceptance tests are done in the USA factory in Trevose, Pennsylvania to ensure that the system is functioning properly and is within the full range of operating specifications. Spare parts are also available for ease of access.

Esco VacciXcell will be displaying the new TideCell® in the following conferences and exhibitions. Come and meet them at the following events to learn more about the leading-edge technologies VacciXcell offers.

 

 

BioProcessing International Conference and Exhibition

World Vaccine and Immunotherapy

September 25-28, 2017

Booth 1329

Hynes Convention Center

Boston, MA

November 30 – December 1, 2017

Booth 11

Loews Coronado Bay Resort

San Diego, CA

 

Learn more about bioprocessing by visiting www.vaccixcell.com